A PHASE 1/2, OPEN-LABEL, MULTI-ARM TRIAL TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, BIOLOGICAL, AND CLINICAL ACTIVITY OF AGEN1884 IN COMBINATION WITH AGEN2034 IN SUBJECTS WITH METASTATIC OR LOCALLY ADVANCED SOLID TUMORS, AND EXPANSION INTO SELECT SOLID TUMORS
2018-000120-33ESCALADO DOSIS EN PACIENTES CON TUMOR SÓLIDO METASTÁSICOFundación Jiménez DíazInvestigador: DOGER DE SPEVILLE BERNARD
